Synopsis

PET/MRI provides multi-parametric evaluation in cancer staging and serve as hybrid biomarkers.

Hybrid imaging biomarkers may have association with pathological prognostic factors and survival. In endometrial cancer, SUVmax/ADCmin represented higher tumor metabolism and cellularity; and correlated with pathological prognostic factors. In pancreatic ductal adenocarcinoma, hybrid biomarker (MTV/ADCmin) showed negative correlation in progression-free survival. Patients with higher values of TLG or TLG/Peak ratio have shorter overall survival. In esophageal cancer, MTV/ADCmin may predict overall survival. In further, PET can make MR reading easier for lymphadenopathy and systemic staging.

PET/MR can pave to precision medicine and better convenience for the aging society.